Log In Sign up
The largest database of trusted experimental protocols
> Disorders > Sign or Symptom > Ageusia

Ageusia

Ageusia is the complete lack of taste perception, resulting in an inability to detect the five basic taste sensations: sweet, sour, salt, bitter, and umami.
This condition can be caused by various factors, such as head trauma, certain medications, or underlying medical conditions affecting the gustatory nerve or taste bud function.
Individuals with ageusia may experience a diminished quality of life due to the inability to fully enjoy food and beverages.
Accurate diagnosis and identification of the underlying cause are crucial for effective management and potential treatment options.
Researchers can leverage the power of AI-driven tools like PubCompare.ai to optimize their ageusia studies, enhancing reproducibility and accuracy in their findings.

Most cited protocols related to «Ageusia»

1
Efficacy of BNT162b2 against COVID-19
The first primary end point was the efficacy of BNT162b2 against confirmed Covid-19 with onset at least 7 days after the second dose in participants who had been without serologic or virologic evidence of SARS-CoV-2 infection up to 7 days after the second dose; the second primary end point was efficacy in participants with and participants without evidence of prior infection. Confirmed Covid-19 was defined according to the Food and Drug Administration (FDA) criteria as the presence of at least one of the following symptoms: fever, new or increased cough, new or increased shortness of breath, chills, new or increased muscle pain, new loss of taste or smell, sore throat, diarrhea, or vomiting, combined with a respiratory specimen obtained during the symptomatic period or within 4 days before or after it that was positive for SARS-CoV-2 by nucleic acid amplification–based testing, either at the central laboratory or at a local testing facility (using a protocol-defined acceptable test).
Major secondary end points included the efficacy of BNT162b2 against severe Covid-19. Severe Covid-19 is defined by the FDA as confirmed Covid-19 with one of the following additional features: clinical signs at rest that are indicative of severe systemic illness; respiratory failure; evidence of shock; significant acute renal, hepatic, or neurologic dysfunction; admission to an intensive care unit; or death. Details are provided in the protocol.
An explanation of the various denominator values for use in assessing the results of the trial is provided in Table S1 in the Supplementary Appendix, available at NEJM.org. In brief, the safety population includes persons 16 years of age or older; a total of 43,448 participants constituted the population of enrolled persons injected with the vaccine or placebo. The main safety subset as defined by the FDA, with a median of 2 months of follow-up as of October 9, 2020, consisted of 37,706 persons, and the reactogenicity subset consisted of 8183 persons. The modified intention-to-treat (mITT) efficacy population includes all age groups 12 years of age or older (43,355 persons; 100 participants who were 12 to 15 years of age contributed to person-time years but included no cases). The number of persons who could be evaluated for efficacy 7 days after the second dose and who had no evidence of prior infection was 36,523, and the number of persons who could be evaluated 7 days after the second dose with or without evidence of prior infection was 40,137.
Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Pérez Marc G., Moreira E.D., Zerbini C., Bailey R., Swanson K.A., Roychoudhury S., Koury K., Li P., Kalina W.V., Cooper D., Frenck RW J.r., Hammitt L.L., Türeci Ö., Nell H., Schaefer A., Ünal S., Tresnan D.B., Mather S., Dormitzer P.R., Şahin U., Jansen K.U, & Gruber W.C. (2020). Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. The New England Journal of Medicine.
Publication 2020
Age Groups Ageusia BNT162B2 Chills Cough COVID 19 Diarrhea Dyspnea Fever Infection Kidney Myalgia Nucleic Acid Amplification Tests Placebos Respiratory Failure Respiratory Rate Safety SARS-CoV-2 Sense of Smell Shock Sore Throat Vaccines
2
COVID-19 Vaccine Clinical Trial

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2020
Adult Ageusia Anti-Antibodies Antibodies BLOOD Complete Blood Count Cough COVID 19 Dyspnea Eligibility Determination Ethics Committees, Research Fever Forehead Glucose Health Personnel Healthy Volunteers Hematuria Hepatitis B Kidney Liver Function Tests Organisms, Genetically Modified Pharmaceutical Preparations Pregnancy Tests Proteins Safety SARS-CoV-2 Urinalysis Vaccines Voluntary Workers Woman
3
Efficacy of ChAdOx1 nCoV-19 Vaccine for COVID-19
The primary objective was to evaluate the efficacy of ChAdOx1 nCoV-19 vaccine against NAAT-confirmed COVID-19. The primary outcome was virologically confirmed, symptomatic COVID-19, defined as a NAAT-positive swab combined with at least one qualifying symptom (fever ≥37·8°C, cough, shortness of breath, or anosmia or ageusia).
All participants were given an emergency 24-h telephone number to contact the on-call study physician for the duration of the study to report any illnesses. Serious adverse events were recorded throughout the study and reviewed at each study visit, with causality assigned by the site investigator. Events were clinically coded according to the Medical Dictionary for Regulatory Activities.
Voysey M., Clemens S.A., Madhi S.A., Weckx L.Y., Folegatti P.M., Aley P.K., Angus B., Baillie V.L., Barnabas S.L., Bhorat Q.E., Bibi S., Briner C., Cicconi P., Collins A.M., Colin-Jones R., Cutland C.L., Darton T.C., Dheda K., Duncan C.J., Emary K.R., Ewer K.J., Fairlie L., Faust S.N., Feng S., Ferreira D.M., Finn A., Goodman A.L., Green C.M., Green C.A., Heath P.T., Hill C., Hill H., Hirsch I., Hodgson S.H., Izu A., Jackson S., Jenkin D., Joe C.C., Kerridge S., Koen A., Kwatra G., Lazarus R., Lawrie A.M., Lelliott A., Libri V., Lillie P.J., Mallory R., Mendes A.V., Milan E.P., Minassian A.M., McGregor A., Morrison H., Mujadidi Y.F., Nana A., O’Reilly P.J., Padayachee S.D., Pittella A., Plested E., Pollock K.M., Ramasamy M.N., Rhead S., Schwarzbold A.V., Singh N., Smith A., Song R., Snape M.D., Sprinz E., Sutherland R.K., Tarrant R., Thomson E.C., Török M.E., Toshner M., Turner D.P., Vekemans J., Villafana T.L., Watson M.E., Williams C.J., Douglas A.D., Hill A.V., Lambe T., Gilbert S.C, & Pollard A.J. (2021). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet (London, England), 397(10269), 99-111.
Full text: Click here
Publication 2021
Ageusia ChAdOx1 nCoV-19 Cough COVID 19 Dyspnea Emergencies Fever Physicians
4
COVID-19 Symptom Identification and Response

Identification of covid-19 symptoms—One question asked participants to identify the most common symptoms of covid-19, with multiple response options allowed (up to four initially, up to five from 25 May 2020, wave 18). We coded participants as having identified symptoms of covid-19 if they selected cough, high temperature or fever, and, from 18 May 2020 (wave 17), either loss of sense of smell or loss of sense of taste. In government guidance these symptoms are actively promoted to members of the UK public as the “main” symptoms of covid-19.20
Fully self-isolating—We measured self-reported self-isolation in participants who indicated that they had experienced symptoms of covid-19 (high temperature or fever, cough, or loss of sense of smell or taste) in the past seven days. Participants were asked for what reason, if any, they had left home since the development of symptoms. We categorised people as non-adherent if they reported leaving home for any reason since symptoms developed. From 26 October 2020 (wave 31) we also asked participants how soon (in days) they had first left home after symptoms developed. We used this to create a second outcome variable (duration adjusted adherence) and categorised people as non-adherent if they reported leaving home for any reason in the first 10 days after symptoms developed. This adjustment allowed for the fact that, during that period, self-isolation was only required for 10 days after symptom onset. We measured intended full self-isolation in participants who had not experienced covid-19 symptoms in the past week. Participants were asked to imagine they developed symptoms of covid-19 (high temperature or fever, new continuous cough, or loss of sense of taste or smell) the next morning and what would cause them to leave home, if anything.
Requesting a test—Participants who reported covid-19 symptoms were asked what actions they had taken when symptoms developed. Response options included “I requested a test to confirm whether I have coronavirus.” In data collected between 1 June and 5 August 2020 (waves 19 to 26), participants who reported requesting a test after symptoms had developed were asked whether the test indicated they had or did not have covid-19 or if they were still waiting for the test results. Participants who reported no covid-19 symptoms were asked what actions they would take if they were to develop symptoms.
Sharing details of close contacts—Participants who had not experienced covid-19 symptoms in the past seven days were asked to imagine they had tested positive for covid-19 and had been prompted by the National Health Service contact tracing service. We asked participants how likely they would then be to share details of people they had been in close contact with on a 5 point scale from “definitely would” to “definitely would not.” We recoded intention to share details of close contacts into a binary variable (probably or definitely would share details versus not sure, probably, or definitely would not). Too few participants indicated that they had tested positive to analyse separately.
Smith L.E., Potts H.W., Amlôt R., Fear N.T., Michie S, & Rubin G.J. (2021). Adherence to the test, trace, and isolate system in the UK: results from 37 nationally representative surveys. The BMJ, 372, n608.
Full text: Click here
Publication 2021
Ageusia Coronavirus Cough COVID 19 Fever Health Services, National isolation Sense of Smell Taste
5
SARS-CoV-2 Testing of Hospital Staff
Oxford University Hospitals offer SARS-CoV-2 testing to all symptomatic and asymptomatic staff working at four teaching hospitals in Oxfordshire, United Kingdom. SARS-CoV-2 PCR testing of combined nasal and oropharyngeal swab specimens for symptomatic staff (those with new persistent cough, temperature ≥37.8°C, or anosmia or ageusia) was offered beginning on March 27, 2020. Asymptomatic health care workers were invited to participate in voluntary nasal and oropharyngeal swab PCR testing every 2 weeks and serologic testing every 2 months (with some participating more frequently for related studies) beginning on April 23, 2020, as previously described.5 ,22 (link) Staff were followed until November 30, 2020. Deidentified data were obtained from the Infections in Oxfordshire Research Database, which has generic research ethics committee, Health Research Authority, and Confidentiality Advisory Group approvals.
Lumley S.F., O’Donnell D., Stoesser N.E., Matthews P.C., Howarth A., Hatch S.B., Marsden B.D., Cox S., James T., Warren F., Peck L.J., Ritter T.G., de Toledo Z., Warren L., Axten D., Cornall R.J., Jones E.Y., Stuart D.I., Screaton G., Ebner D., Hoosdally S., Chand M., Crook D.W., O’Donnell A.M., Conlon C.P., Pouwels K.B., Walker A.S., Peto T.E., Hopkins S., Walker T.M., Jeffery K, & Eyre D.W. (2020). Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers. The New England Journal of Medicine.
Publication 2020
Ageusia Cough Ethics Committees, Research Generic Drugs Health Personnel Infection Nose Oropharynxs SARS-CoV-2

Most recents protocols related to «Ageusia»

1
Characterizing COVID-19 Symptom Presentation
Our primary outcome was the presence and number of presenting symptoms (Table 1) from illness onset until study enrollment. Symptom groups included gastrointestinal, hydration, lower respiratory, musculoskeletal, neurological, rash or oral changes, systemic, and upper respiratory. Anosmia or ageusia, cough, conjunctivitis, and fever were analyzed independently without being grouped with other symptoms. Secondary outcomes included (1) presence of core COVID-19 symptoms (≥1 of ageusia, anosmia, cough, or fever)19 (link); (2) chest radiography performance and treatment provided; and (3) hospitalization, intensive care unit (ICU) admission, and revisits to any ED or to any health care provider (including the ED) within 14 days of the index ED visit.
Sumner M.W., Xie J., Zemek R., Winston K., Freire G., Burstein B., Kam A., Emsley J., Gravel J., Porter R., Sabhaney V., Mater A., Salvadori M.I., Berthelot S., Beer D., Poonai N., Moffatt A., Wright B, & Freedman S.B. (2023). Comparison of Symptoms Associated With SARS-CoV-2 Variants Among Children in Canada. JAMA Network Open, 6(3), e232328.
Full text: Click here
Publication 2023
Ageusia Conjunctivitis Cough COVID 19 Exanthema Fever Health Personnel Hospitalization Radiography, Thoracic Respiratory Rate
2
Detection of Original SARS-CoV-2 Symptoms
The original-type SARS-CoV-2 virus refers to the genomic sequence of SARS-CoV-2 identified from the first cases before the emergence of VoC. Symptoms reported by caregivers were those that were new and/or associated with the current illness. Core COVID-19 symptoms included ageusia, anosmia, cough, or fever,19 (link) defined as a documented temperature of at least 38.0°C in the ED, in the referring clinic or hospital, at home, or a tactile fever.23 (link)
Sumner M.W., Xie J., Zemek R., Winston K., Freire G., Burstein B., Kam A., Emsley J., Gravel J., Porter R., Sabhaney V., Mater A., Salvadori M.I., Berthelot S., Beer D., Poonai N., Moffatt A., Wright B, & Freedman S.B. (2023). Comparison of Symptoms Associated With SARS-CoV-2 Variants Among Children in Canada. JAMA Network Open, 6(3), e232328.
Full text: Click here
Publication 2023
Ageusia Cough COVID 19 Fever Genome SARS-CoV-2
3
Defining SARS-CoV-2 Re-infection Characteristics
Re-infection was defined by the following characteristics: a positive SARS-CoV-2 PCR test or a rapid-antigen test (RAT) more than 90 days (or in some studies 120 days) after a previously positive PCR test or RAT; two positive PCR tests or RATs separated by four consecutive negative PCR tests; or a positive PCR test or RAT in an individual with a positive IgG SARS-CoV-2 anti-spike antibody test. Symptomatic re-infection was defined as re-infection with SARS-CoV-2 that leads to the development of symptoms, which may include but are not limited to fever, new or increased cough, new or increased shortness of breath, chills, new or increased muscle pain, new loss of taste or smell, sore throat, diarrhoea, and vomiting. Severe re-infection was re-infection with SARS-CoV-2 that led to hospitalisation or death.
Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis. (2023). Lancet (London, England), 401(10379), 833-842.
Full text: Click here
Publication 2023
Ageusia Antigens Chills Cough COVID 19 Diarrhea Dyspnea Fever Immunoglobulins Myalgia Rattus norvegicus Reinfection SARS-CoV-2 Sense of Smell Sore Throat
4
Prone Position for COVID-19 ARDS
This multicenter retrospective cohort study was conducted in six hospitals and approved by the Clinical Research Ethics Committee of all centers (31881520.3.1001.5335). Due to the retrospective nature of the study, the need for informed consent was waived. The study included patients under invasive mechanical ventilation with suspected or confirmed SARS-CoV-2 infection, who received prone position sessions for severe COVID-19-ARDS treatment. The inclusion criteria were individuals diagnosed with COVID-19, requiring invasive mechanical ventilation and severe ARDS (PaO2/FiO2 < 150 mmHg). The exclusion criterion was age < 65 years.
Confirmed COVID-19 patients were considered for analysis if they presented a positive real-time reverse transcription-polymerase chain reaction (PCR-RT). Additionally, patients with suspected or negative PCR-RT who presented clinical symptoms of COVID-19, including fever, cough, tiredness, anosmia, ageusia, headache, pain, diarrhea, and/or dyspnea, were also included.
The trained researchers collected data from electronic medical records using standardized forms. All contributors had access to the electronic medical records of their affiliated institutions and were committed to ensuring data protection. Patients were followed up from hospital admission to discharge or death, and the study group did not interfere with medical decisions.
The PaO2/FiO2 ratio was used to assess the oxygenation response. Patients who presented a 20-point improvement in PaO2/FiO2 after the first prone session were considered the responders group. Patients who did not present 20-point of improvement in PaO2/FiO2 after the first prone session were included in the non-responders group. Mortality was defined as deaths that occurred between hospitalization and discharge.
Cunha M.C., Schardong J., Righi N.C., Lunardi A.C., Sant'Anna G.N., Isensee L.P., Xavier R.F., Pompeu J.E., Weigert R.M., Matte D.L., Cardoso R.A., Abras A.C., Silva A.M., Dorneles C.C., Werle R.W., Starke A.C., Ferreira J.C., Plentz R.D, & Carvalho C.R. (2023). Aging-related predictive factors for oxygenation improvement and mortality in COVID-19 and acute respiratory distress syndrome (ARDS) patients exposed to prone position: A multicenter cohort study. Clinics, 78, 100180.
Full text: Click here
Publication 2023
Ageusia Cell Respiration Cough COVID 19 Diarrhea Dyspnea Ethics Committees, Research Fatigue Fever Headache Hospitalization Mechanical Ventilation Pain Patient Discharge Patients Polymerase Chain Reaction Real-Time Polymerase Chain Reaction Respiratory Distress Syndrome, Adult Reverse Transcription
5
Investigating COVID-19 Sequelae and Survival

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2023
Ageusia Arthralgia Cacosmia COVID 19 Diagnosis Disorders, Cognitive Dyspnea Fatigue Fever Headache Kidney Lethargy Muscle Cramp Patients Pregnancy, Prolonged sequels Signs and Symptoms, Respiratory Skin Diseases

Top products related to «Ageusia»

1
Stata v 15 by StataCorp
Sourced in United States, Austria, Australia
Stata V.15 is a comprehensive statistical software package that provides a wide range of data analysis and management tools. It offers features for data manipulation, statistical modeling, graphics, and programming. Stata V.15 is designed to handle complex data structures and provide advanced analytical capabilities for researchers, analysts, and professionals across various fields.
2
Cobas 8000 by Roche
Sourced in Switzerland, Germany, United States, Japan, France, Italy, China, United Kingdom, Sweden
The Cobas 8000 is a modular, automated in-vitro diagnostic system designed for high-throughput clinical chemistry and immunochemistry testing. It is used to perform a wide range of laboratory tests, including those for chemistry, immunoassay, and electrolyte analysis. The Cobas 8000 is capable of processing a large volume of samples efficiently and accurately.
3
Spss statistics version 22 by IBM
Sourced in United States, Japan, United Kingdom, Germany, Belgium, Australia, Spain, Switzerland
SPSS Statistics version 22 is a statistical software application developed by IBM. It is designed to analyze and manipulate data, providing users with tools for data management, statistical analysis, and reporting. The software supports a wide range of data types and offers a variety of statistical procedures, enabling users to explore relationships, test hypotheses, and generate insights from their data.
4
Spss statistical software by IBM
Sourced in United States, Japan, United Kingdom, Belgium, Austria, Australia, Spain
SPSS is a comprehensive statistical software package that enables data analysis, data management, and data visualization. It provides a wide range of statistical techniques, including descriptive statistics, bivariate analysis, predictive analytics, and advanced modeling. SPSS is designed to help users efficiently manage and analyze large datasets, making it a valuable tool for researchers, statisticians, and data analysts.
5
Stata 12 by StataCorp
Sourced in United States, United Kingdom, Denmark, Belgium, Spain, Canada, Austria
Stata 12.0 is a comprehensive statistical software package designed for data analysis, management, and visualization. It provides a wide range of statistical tools and techniques to assist researchers, analysts, and professionals in various fields. Stata 12.0 offers capabilities for tasks such as data manipulation, regression analysis, time-series analysis, and more. The software is available for multiple operating systems.
6
Realtime sars cov 2 assay by Abbott
Sourced in United States
The RealTime SARS-CoV-2 assay is a laboratory diagnostic test designed to detect the presence of the SARS-CoV-2 virus, the causative agent of COVID-19. The assay utilizes real-time reverse transcription-polymerase chain reaction (RT-PCR) technology to identify the genetic material of the virus in patient samples.
7
R version 4 by R Project for Statistical Computing
Sourced in United States, Austria, Japan, Belgium, New Zealand, Denmark
R version 4.0.2 is the latest stable release of the R Project for Statistical Computing, a free and open-source software environment for statistical computing and graphics. R version 4.0.2 provides a wide range of statistical and graphical techniques, and is widely used in various fields for data analysis, visualization, and modeling.
8
Stata 14 by StataCorp
Sourced in United States, Denmark, United Kingdom, Belgium, Japan, Austria, China
Stata 14 is a comprehensive statistical software package that provides a wide range of data analysis and management tools. It is designed to help users organize, analyze, and visualize data effectively. Stata 14 offers a user-friendly interface, advanced statistical methods, and powerful programming capabilities.
9
Stata version 14 by StataCorp
Sourced in United States, Denmark, Austria, United Kingdom, Japan, Canada
Stata version 14 is a software package for data analysis, statistical modeling, and graphics. It provides a comprehensive set of tools for data management, analysis, and reporting. Stata version 14 includes a wide range of statistical techniques, including linear regression, logistic regression, time series analysis, and more. The software is designed to be user-friendly and offers a variety of data visualization options.
10
Spss statistics for windows version 20 by IBM
Sourced in United States, United Kingdom, Germany
SPSS Statistics for Windows, Version 20.0 is a software application for statistical analysis. It provides tools for data management, visualization, and advanced statistical modeling. The software is designed to work on the Windows operating system.

More about "Ageusia"

Ageusia, the complete lack of taste perception, is a condition that can significantly impact an individual's quality of life.
This inability to detect the five basic taste sensations - sweet, sour, salt, bitter, and umami - can be caused by various factors, including head trauma, certain medications, or underlying medical conditions affecting the gustatory nerve or taste bud function.
Researchers studying ageusia can leverage the power of AI-driven tools like PubCompare.ai to optimize their research.
This platform can help locate the best protocols for ageusia from literature, pre-prints, and patents, using intelligent comparison tools to enhance reproducibility and accuracy in their findings.
Accurate diagnosis and identification of the underlying cause of ageusia are crucial for effective management and potential treatment options.
Individuals with ageusia may experience a diminished enjoyment of food and beverages, leading to a reduced quality of life.
Statistical analysis software like Stata V.15, SPSS Statistics version 22, and R version 4.0.2 can be utilized to analyze data and draw insights from ageusia studies.
Additionally, diagnostic tools like the Cobas 8000 and RealTime SARS-CoV-2 assay can be employed to aid in the assessment and management of ageusia.
By incorporating the latest research, technology, and statistical methods, researchers can gain a deeper understanding of ageusia and develop more effective strategies for its treatment and management.
Thsi will ultimately improve the quality of life for those affected by this condition.